New Identification Method for Cancerous DNA to Reduce Need for Painful Biopsy Surgery
|
By LabMedica International staff writers Posted on 09 Sep 2024 |
|
Currently, most cancer patients must undergo an invasive and expensive surgical biopsy to remove a tissue sample from their tumor to determine the best treatment options. However, all individuals have small amounts of DNA that circulate freely in their blood, which is not confined within blood cells. In cancer patients, some of this circulating free DNA (ctDNA) originates from their tumors. This ctDNA differs from their normal circulating DNA as it carries mutations that have turned these cells from healthy to cancerous. Thus, ctDNA can provide insights into the cancer's characteristics and indicate which treatments might be most effective. Existing methods to analyze ctDNA are hampered by its low abundance and the presence of a larger quantity of non-cancerous DNA in the blood samples.
Researchers at Heriot-Watt University (Edinburgh, UK) are now developing a novel method to identify cancerous DNA that could reduce the need for painful biopsies. This new technique, known as SNARE, aims to simplify the processing of blood samples to enhance the detection and characterization of cancerous DNA. The team is working on creating both robotic benchtop systems and microfluidic platforms (similar to certain types of lateral flow tests) and will evaluate these methods using blood samples from breast cancer patients to achieve more sensitive ctDNA detection and reduce the need for expensive DNA sequencing.
In patients with advanced-stage cancer, significant amounts of DNA in the bloodstream can often be detected, but by this stage, it is frequently too late for a cure. On the other hand, in early-stage cancer patients, where treatment success rates are higher, over 99% of the circulating free DNA typically originates from healthy cells, complicating the identification of cancerous mutations. The Heriot-Watt research team plans to further develop MicroSNARE, which they have already tested in the lab, with the aim of diagnosing, analyzing, and characterizing tumors at an earlier stage. They also aim to detect cancer recurrence before it can progress and spread. MicroSNARE promises a groundbreaking, less invasive approach to cancer detection, potentially enabling earlier diagnosis and intervention.
Related Links:
Heriot-Watt University
Latest Pathology News
- New Journal Addresses Evolving Needs in Clinical and Translational Pathology
- AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells
- AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
- New Review Highlights Intelligent Agents as Next Step for Digital Pathology
- Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
- AI Links Organ-Specific Aging Patterns in Histology to Blood-Based Signals
- 30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
- AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
- AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
- FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
- AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
- AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
- PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
- AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
- AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
- Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Channels
Clinical Chemistry
view channel
NIH-Funded Study Targets Saliva-Based Long COVID Diagnosis
Long COVID presents with heterogeneous, persistent symptoms that complicate clinical assessment and case definition. A lack of a definitive diagnostic test forces clinicians to exclude alternative etiologies... Read more
Validated Biomarker Blood Test Detects Early Lung Cancer and Supports Risk Assessment
Lung cancer is often diagnosed at advanced stages because symptoms typically appear late, while participation in low-dose computed tomography (LDCT) screening remains low. Imaging can also produce false-positive... Read more
Machine Learning Model Uses Routine Lab Tests to Support Heart Failure Classification
Accurately distinguishing heart failure phenotypes is important for guiding imaging and treatment decisions in hospital care, but phenotyping usually depends on echocardiography, which may not be immediately... Read more
Molecular Diagnostics
view channel
Single-Tube CRISPR Test Detects Pathogens and Genetic Variants in 30 Minutes
Rapid, accurate detection of infectious agents and single-nucleotide variants remains difficult to deliver outside centralized laboratories. Although multi-step nucleic acid workflows are sensitive, they... Read more
New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients
Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more
Hematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Immunology
view channel
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read more
Microbiology
view channel
New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Technology
view channel
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read more
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Industry
view channel
Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial
ANatera’s Signatera test will be used in a partnership with Angiex to evaluate patients receiving AGX101, a Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) in a Phase I clinical trial.... Read more
